Gilead upgrades 2026 sales outlook as HIV drug Biktarvy and Livdelzi show strong growth

Gilead Sciences reported strong first-half 2026 momentum with key drugs Biktarvy and Livdelzi driving sales growth. Biktarvy sales rose 6.9% year-over-year to about $3.77 billion in Q2, while Livdelzi revenue more than doubled to $167 million. Despite weak demand for COVID antiviral Veklury, Gilead raised its full-year 2026 sales forecast to $30.1-$30.4 billion. This positive performance led analysts to upgrade Gilead's rating from 'Hold' to 'Buy', signaling confidence in its growth prospects.